Low estrogen after menopause drives genitourinary syndrome of menopause.

Genitourinary Syndrome of Menopause (GSM) is a chronic, progressive condition affecting a significant portion of postmenopausal individuals. The decline in circulating estradiol is the primary driver of these anatomical and functional changes in the lower reproductive and urinary tracts.

Clinical evidence

Large-scale clinical research and consensus from organizations like the North American Menopause Society (NAMS) and the American College of Obstetricians and Gynecologists (ACOG) confirm that estrogen deficiency leads to measurable tissue atrophy.

• Vaginal health: Research indicates that the loss of estrogen shifts the vaginal maturation index (VMI), increasing the ratio of parabasal cells to superficial cells. This results in a thin, fragile mucosal layer prone to irritation and bleeding.
• Urinary symptoms: Randomized controlled trials (RCTs) demonstrate that estrogen withdrawal affects the bladder and urethra, contributing to increased urinary frequency, urgency, and stress or urge incontinence. Systematic reviews show that local (vaginal) estrogen therapy can reduce daily voids by 1–2 per 24 hours, providing significant symptom relief.
• Dyspareunia and lubrication: The loss of glycogen-rich epithelium leads to a rise in vaginal pH and a reduction in natural lubrication. These structural changes directly correlate with high rates of dyspareunia (painful intercourse) reported by postmenopausal patients.

Mechanistic explanations

The pathophysiology of GSM is driven by the density of estrogen receptors (ERα and ERβ) throughout the vulvovaginal and urogenital tissues, which share a common embryonic origin in the urogenital sinus.

• Cellular level: Estrogen signaling maintains epithelial cell proliferation and the production of extracellular matrix components, including collagen, elastin, and hyaluronic acid.
• Microbiome and pH: Estrogen promotes the accumulation of glycogen in vaginal cells. When these cells slough off, Lactobacilli metabolize the glycogen into lactic acid, maintaining an acidic pH (3.5–4.5). Post-menopause, the loss of this mechanism leads to a more alkaline environment, altering the local microbiome and increasing susceptibility to urinary tract infections (UTIs).
• Vascular and structural impact: Estrogen maintains periurethral vascularity and the integrity of the glycosaminoglycan (GAG) layer in the bladder. Its absence leads to diminished blood flow and thinning of the urothelium, exacerbating urinary sensitivity.

Bottom line

Scientific evidence strongly supports that low estrogen signaling post-menopause is the primary driver of vaginal atrophy, reduced lubrication, dyspareunia, and urinary dysfunction. These symptoms are effectively managed and often reversed through targeted local estrogen therapy.